The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term ...

A new study in JAMA contradicts a series of statements made by HHS Secretary Robert F. Kennedy Jr. that paint vaccine ...

Adaptive Biotechnologies lost a powerhouse partner after Roche subsidiary Genentech walked away from a potentially $2 billion ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

A draft copy of the Make America Healthy Again Commission’s latest report, obtained by Politico, focuses on vaccine-related ...